|
|
 |
|
Viewing report
|
|
|
|
Targeted Cancer Therapies: Innovative Drugs And Their Impact On The Future Of Oncology
Business Insights, Aug 2004, Pages: 155
The 'Targeted Cancer Therapies: Innovative drugs and their impact on the future of oncology' management report assesses the role of targeted cancer therapies as a driver of growth in the cancer market and their future role potential.
Drugs for high-severity conditions grew over the past decade at over twice the rate of drugs for low severity conditions, traditionally served by primary care blockbuster drugs. Increasingly, pharmaceutical companies are breaking into the cancer market through brands that are launched as a therapy for a minor indication and subsequently developed for other indications and first-in-line therapies.
The new wave of innovation is being led by European companies and could bring about a revolution not only in cancer treatment, but across the industry as a whole. This report provides detailed analysis of innovation in both the diagnosis and treatment of cancer and forecasts for the success of leading drugs, enabling your company to plan effective oncology strategies.
Hot issues covered in this report:
The attractiveness of targeted therapies
- A review of pipeline activity shows that oncology-related products account for almost 30% of all activity. This reflects the need for innovative therapies and the high drug price levels they command due to unmet needs.
The impact of targeted therapies on the cancer market
- Targeted therapies are forecast high growth rates against a backdrop of a slow growth cancer market. The ongoing success of specialized medicines will have a continued impact on the more traditional blockbuster model.
Progress in oncogenics
- Progress in oncogenics means an accelerated stream of novel targets for small molecule drugs, shorter timelines between discovery of new gene targets and drugs and also high throughput screening enabling quicker development.
“With a mortality rate of more than 9 %, prostate carcinoma ranks 3rd among the most common causes of death by cancer in men, following lung and colon cancer. Ethnicity plays a role in this type of cancer, as the mortality rate is twice as high in Afro-Americans as in Caucasians…”
Why you should order your copy today:
This report will help you to...
- Analyze the key drivers of success and discover how they are moving companies away from the traditional blockbuster model.
- Identify the most succesful strategies behind innovative cancer therapies in the marketplace with case studies from Roche, Astra Zeneca and Genetentech.
- Understand the developments in oncogenics and the impact on improving the timelines of drug discovery.
- Assess the importance of new diagnostic tools and the impact of genetic counseling on treatment patterns.
- Quantify the future sales of pioneering cancer drugs the epidemiology underpinning their growth and the competitive threats facing brand leaders.
“In-house development dominates the pre-clinical stage, accounting for 91% of projects. The percentage of in-house sourced drugs falls to 68.5% in Phase I, 63.6% in Phase II and 57.4% in Phase III. Conversely, the proportion of in-licensed drugs increases as development progresses...”
“Roche’s oncology brands were a key driver of the company’s prescription business growth in 2003. Its oncology franchise contributed SwFr 6bn (30% higher than in 2002) to the company’s prescription product sales of SwFr 21.6b...”
This report will provide the answers to your questions, such as...
- What is the impact of declining R&D productivity on the future of cancer drug discovery?
- What advances are being made in the diagnosis of cancer?
- What are the unmet needs in cancer treatment?
- What new treatments are being developed in areas such as breast cancer, colorectal cancer and prostate cancer?
- Who are the key players and what lessons do they provide about the future of targeted cancer therapies?
- What are the sales forecasts for key brands such as Tarceva and Eloxatin?
- How will targeted therapies help change the structure of the pharmaceutical industry?
“The market for cancer therapies grew slowly from 1980 to 2000, mainly because of the lack of significant progress in therapeutic innovation. Growth has come with first the launch of the taxan products, and, secondly, with the appearance of the new molecules EPO, G-CSF for the treatment of anemia and neutropenia induced by chemotherapies...”
Key findings of the report
- Pharmaceutical R&D yields no economies of scale, leading to a performance gap in which expenditure is increasing while the number of NCEs launched decreases.
- Targeted therapies are forecast to show the highest growth rate in the next four years, compared to chemotherapies, hormonal therapies and hematopoietic growth factors - 90% between 2004 and 2008.
- New diagnostic tools could have a major effect on cancer treatment, aiding oncologists to decide on patient-specific therapies for cancer patients and increasing survival rates through early detection of tumors.
- Avastin is forecast to have sales of $3,110m in 2009, up from forecast sales of $1,285m in 2005. The drug's impressive clinical trials performance has had a radical impact on Genentech's share price - almost 200% between June 2003 and June 2004.
Customers who bought this item also bought
The Targeted Cancer Therapies Pipeline: A Strategic Review
Dealmaking and Industry Outlook: Targeted Cancer Therapies
Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Pricing and Reimbursement of Targeted Cancer Therapies
Drug Delivery Technology - Revolutionizing Cancer Therapies
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Gastric Cancer - Targeted Therapies Compete for First-to-Market Status
Prostate and Breast Cancer- New Treatments & Developmental Progress
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Commercial Insight: Antihormonal Cancer Therapies
|
|
|
|
